{
    "Trade/Device Name(s)": [
        "OncoMate MSI Dx Analysis System",
        "OncoMate MSI Dx Interpretive Software",
        "OncoMate 5C Matrix Standard"
    ],
    "Submitter Information": "Promega Corporation",
    "510(k) Number": "K200129",
    "Predicate Device Reference 510(k) Number(s)": [
        "DEN170030"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "PZJ"
    ],
    "Summary Letter Date": "November 30, 2020",
    "Summary Letter Received Date": "December 1, 2020",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 864.1866"
    ],
    "Regulation Name(s)": [
        "Lynch Syndrome Test Systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "cancer molecular"
    ],
    "Analyte(s)": [
        "BAT-25",
        "BAT-26",
        "NR-21",
        "NR-24",
        "MONO-27",
        "Penta C",
        "Penta D"
    ],
    "Specimen Type(s)": [
        "Formalin fixed paraffin-embedded (FFPE) colorectal tissue sections",
        "Normal tissue",
        "Tumor tissue"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Applied Biosystems 3500Dx Genetic Analyzer",
        "Maxwell CSC Instrument",
        "Thermal cycler (compatible with 96-well plates or reaction tubes)",
        "Fluorometer (compatible with fluorescent-dye-based dsDNA quantification)",
        "OncoMate MSI Dx Interpretive Software"
    ],
    "Method(s)/Technology(ies)": [
        "Multiplex polymerase chain reaction (PCR)",
        "Capillary electrophoresis",
        "Fluorescence-based DNA detection"
    ],
    "Methodologies": [
        "Microsatellite instability detection",
        "DNA fragment length analysis",
        "Genetic variant analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Software",
        "Reagent",
        "Kit",
        "Control",
        "Standard",
        "System"
    ],
    "Document Summary": "FDA 510(k) summary for OncoMate MSI Dx Analysis System for qualitative multiplex PCR-based detection of microsatellite instability in colorectal cancer to identify probable Lynch syndrome candidates",
    "Indications for Use Summary": "Intended for qualitative multiplex PCR detection of deletions in five mononucleotide microsatellite loci using matched tumor and normal DNA from FFPE colorectal tissue sections to identify microsatellite instability in colorectal cancer patients as an aid in identifying those who may benefit from additional genetic testing for Lynch syndrome",
    "fda_folder": "Immunology"
}